Daewoong
As of the edition of 20 October 2026, Daewoong runs 78 drugs, 1 of them marketed; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 3 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 12 |
| Went quiet | 26 |
| Stopped | 7 |
| Status not established | 32 |
| Total | 78 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Choline alfoscerate | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| TRPV1 Transient receptor potential cation channel subfamily V member 1 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Daewoong needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 17 trials led
- Hormones: 13 trials led
- Digestive system: 10 trials led